Literature DB >> 31194862

A mouse model of Proteus syndrome.

Marjorie J Lindhurst1, Lauren R Brinster2, Hannah C Kondolf1, Jasmine J Shwetar1, Miranda R Yourick1, Henoke Shiferaw1, Kim M Keppler-Noreuil1, Gene Elliot3, Cecilia Rivas3, Lisa Garrett3, Julio Gomez-Rodriguez3, Neil J Sebire4, Stephen M Hewitt5, Pamela L Schwartzberg3, Leslie G Biesecker1.   

Abstract

Proteus syndrome is a mosaic, progressive overgrowth disorder caused by a somatic activating variant c.49G > A p.(E17K) in AKT1. The presentation in affected individuals is variable, with a diversity of tissues demonstrating abnormalities. Common manifestations include skin and bony overgrowth, vascular malformations (VMs), cysts and benign tumors. We used two methods to create mouse models that had endogenously-regulated mosaic expression of the Proteus syndrome variant. Variant allele fractions (VAFs) ranged from 0% to 50% across numerous tissues in 44 Proteus syndrome mice. Mice were phenotypically heterogeneous with lesions rarely observed before 12 months of age. VMs were the most frequent finding with a total of 69 found in 29 of 44 Proteus syndrome mice. Twenty-eight cysts and ectasia, frequently biliary, were seen in 22 of 44 Proteus syndrome mice. Varying levels of mammary hyperplasia were seen in 10 of 16 female Proteus syndrome mice with other localized regions of hyperplasia and stromal expansion noted in several additional animals. Interestingly, 27 of 31 Proteus syndrome animals had non-zero blood VAF that is in contrast to the human disorder where it is rarely seen in peripheral blood. Identification of variant-positive cells by green fluorescent protein (GFP) staining in chimeric Proteus syndrome mice showed that in some lesions, hyperplastic cells were predominantly GFP/Akt1E17K-positive and showed increased pAKT signal compared to GFP-negative cells. However, hyperplastic mammary epithelium was a mixture of GFP/Akt1E17K-positive and negative cells with some GFP/Akt1E17K-negative cells also having increased pAKT signal suggesting that the variant-positive cells can induce lesion formation in a non-cell autonomous manner. Published by Oxford University Press 2019.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31194862      PMCID: PMC6736390          DOI: 10.1093/hmg/ddz116

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  31 in total

Review 1.  Pathobiology of aging mice and GEM: background strains and experimental design.

Authors:  C F Brayton; P M Treuting; J M Ward
Journal:  Vet Pathol       Date:  2012-01       Impact factor: 2.221

Review 2.  The challenges of Proteus syndrome: diagnosis and management.

Authors:  Leslie Biesecker
Journal:  Eur J Hum Genet       Date:  2006-08-02       Impact factor: 4.246

3.  Morphological characterization of the breast in Proteus syndrome complicated by ductal carcinoma in situ.

Authors:  Jabed Iqbal; Gary He; Leslie G Biesecker; Peter Rosen; Paul H Duray; Douglas Schwartzentruber; Mansor Beg; Ellen Kahn
Journal:  Ann Clin Lab Sci       Date:  2006       Impact factor: 1.256

4.  Proteus syndrome: course of a severe case.

Authors:  A Malamitsi-Puchner; D Dimitriadis; C Bartsocas; H R Wiedemann
Journal:  Am J Med Genet       Date:  1990-02

5.  Neoplastic and nonneoplastic lesions in aging mice of unique and common inbred strains contribution to modeling of human neoplastic diseases.

Authors:  H Szymanska; J Lechowska-Piskorowska; E Krysiak; A Strzalkowska; K Unrug-Bielawska; B Grygalewicz; H M Skurzak; B Pienkowska-Grela; M Gajewska
Journal:  Vet Pathol       Date:  2013-09-09       Impact factor: 2.221

6.  A mosaic activating mutation in AKT1 associated with the Proteus syndrome.

Authors:  Marjorie J Lindhurst; Julie C Sapp; Jamie K Teer; Jennifer J Johnston; Erin M Finn; Kathryn Peters; Joyce Turner; Jennifer L Cannons; David Bick; Laurel Blakemore; Catherine Blumhorst; Knut Brockmann; Peter Calder; Natasha Cherman; Matthew A Deardorff; David B Everman; Gretchen Golas; Robert M Greenstein; B Maya Kato; Kim M Keppler-Noreuil; Sergei A Kuznetsov; Richard T Miyamoto; Kurt Newman; David Ng; Kevin O'Brien; Steven Rothenberg; Douglas J Schwartzentruber; Virender Singhal; Roberto Tirabosco; Joseph Upton; Shlomo Wientroub; Elaine H Zackai; Kimberly Hoag; Tracey Whitewood-Neal; Pamela G Robey; Pamela L Schwartzberg; Thomas N Darling; Laura L Tosi; James C Mullikin; Leslie G Biesecker
Journal:  N Engl J Med       Date:  2011-07-27       Impact factor: 91.245

7.  Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin.

Authors:  Thuy L Phung; Keren Ziv; Donnette Dabydeen; Godfred Eyiah-Mensah; Marcela Riveros; Carole Perruzzi; Jingfang Sun; Rita A Monahan-Earley; Ichiro Shiojima; Janice A Nagy; Michelle I Lin; Kenneth Walsh; Ann M Dvorak; David M Briscoe; Michal Neeman; William C Sessa; Harold F Dvorak; Laura E Benjamin
Journal:  Cancer Cell       Date:  2006-08       Impact factor: 31.743

8.  Constitutively active Akt induces ectodermal defects and impaired bone morphogenetic protein signaling.

Authors:  Carmen Segrelles; Marta Moral; Corina Lorz; Mirentxu Santos; Jerry Lu; José Luis Cascallana; M Fernanda Lara; Steve Carbajal; Ana Belén Martínez-Cruz; Ramón García-Escudero; Linda Beltran; José C Segovia; Ana Bravo; John DiGiovanni; Jesús M Paramio
Journal:  Mol Biol Cell       Date:  2007-10-24       Impact factor: 4.138

9.  Primary endothelial cells isolated from the yolk sac and para-aortic splanchnopleura support the expansion of adult marrow stem cells in vitro.

Authors:  Weiming Li; Scott A Johnson; William C Shelley; Michael Ferkowicz; Paul Morrison; Yanjun Li; Mervin C Yoder
Journal:  Blood       Date:  2003-07-31       Impact factor: 22.113

10.  Practical pathology of aging mice.

Authors:  Christina Pettan-Brewer; Piper M Treuting
Journal:  Pathobiol Aging Age Relat Dis       Date:  2011-06-01
View more
  5 in total

Review 1.  The duality of human oncoproteins: drivers of cancer and congenital disorders.

Authors:  Pau Castel; Katherine A Rauen; Frank McCormick
Journal:  Nat Rev Cancer       Date:  2020-04-27       Impact factor: 60.716

2.  Ubiquitous expression of Akt1 p.(E17K) results in vascular defects and embryonic lethality in mice.

Authors:  Marjorie J Lindhurst; Wenling Li; Nathaniel Laughner; Jasmine J Shwetar; Hannah C Kondolf; Xuefei Ma; Yoh-Suke Mukouyama; Leslie G Biesecker
Journal:  Hum Mol Genet       Date:  2020-12-18       Impact factor: 6.150

3.  Clinical Phenotype and Bone Biopsy Characteristics in a Child with Proteus Syndrome.

Authors:  Ali Al Kaissi; Barbara M Misof; Franco Laccone; Stéphane Blouin; Paul Roschger; Susanne G Kircher; Mohammad Shboul; Gabriel T Mindler; Werner Girsch; Rudolf Ganger
Journal:  Calcif Tissue Int       Date:  2021-05-18       Impact factor: 4.333

4.  Late-onset Proteus syndrome with cerebriform connective tissue nevus and subsequent development of intraductal papilloma.

Authors:  Emily W Modlin; Anne M Slavotinek; Thomas N Darling; Stanley Lipkowitz; Frederic G Barr; Pamela N Munster; Leslie G Biesecker; Christopher A Ours
Journal:  Am J Med Genet A       Date:  2022-04-20       Impact factor: 2.578

Review 5.  PI3K inhibitors are finally coming of age.

Authors:  Bart Vanhaesebroeck; Matthew W D Perry; Jennifer R Brown; Fabrice André; Klaus Okkenhaug
Journal:  Nat Rev Drug Discov       Date:  2021-06-14       Impact factor: 112.288

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.